Učitavanje...
Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
OBJECTIVE: To provide the first clinical report that 2 calcitonin gene-related peptide (CGRP) therapies, a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody, can be used concomitantly to treat refractory migraine. METHODS: Case reports are presented of 2 patients participati...
Spremljeno u:
| Izdano u: | Neurology |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Lippincott Williams & Wilkins
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7526667/ https://ncbi.nlm.nih.gov/pubmed/31932515 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000008944 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|